Back

Alveus starts Phase 2 trial of ALV-100 for sustained weight loss

Verifying
  • Alveus Therapeutics launched the Phase 2 PRESERVE trial and dosed its first ALV-100 patient.
  • Approximately 220 participants will receive treatment or placebo for 24 weeks.
  • Participants must have lost at least 10% of body weight on semaglutide.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Alveus starts Phase 2 trial of ALV-100 for sustained weight loss - CoinPost Terminal